Com.Pl.i.t DX Lung is a multigene test designed to help you and your physician make informed treatment decisions based on the unique biology of your tumor and individualize your treatment.
Complit DX Lung is designed in order to allow you and your physician to select which is the optimal treatment for your diagnosis based on the biology of your tumor.
Different Com.Pl.i.t DX Lung panels are designed based for patients with Non-Small-Cell-Lung Cancer.
The test includes the following genes:
|
27 Gene Alterations |
|||||||||
|
AKT1 |
ALK |
BRAF |
CDKN2A |
CTNNB1 |
DDR2 |
EGFR |
ERBB2 |
FBXW7 |
FGFR1 |
|
FGFR2 |
FGFR3 |
HRAS |
KEAP |
KRAS |
MAP2K1 |
MET* |
NOTCH1 |
NRAS |
PIK3CA |
|
POLE |
PTEN |
RET |
SMAD4 |
SMARCA4 |
STK11 |
TP53 |
|
|
|
|
* MET amplification and MET exon 14 skipping are also included in the analysis |
|||||||||
|
7 Fusion Transcripts |
|||||||
|
ALK |
ROS1 |
RET |
NTRK1 |
NTRK2 |
NTRK3 |
MET |
|
The Com.Pl.i.t DX Lung assay provides valuable information that can be utilized for selecting the optimal targeted treatment for patients. By analyzing many genes at the same time it provides a detailed blueprint of the biology of the tumor, which is used by the treating physician to individualize the patient’s treatment plan.
Com.pl.i.t DX Lung is a comprehensive molecular profile for NSCLC patients with prognostic and mainly predictive value, using, according to the guidelines, the correct methodology for the 9 approved targeted therapies:
An individualized report that summarizes the findings of the biology of your tumor is provided to you and your physician.
Genekor takes care of all the logistics in order for your sample to arrive to our laboratory safely.
Our team of experts is here to interpret your results to you and your treating physician.
It is designed for patients with lung cancer. It can also be used in other types of solid tumors including those of unknown origin.
The results of the Com.Pl.i.t DX Lung Assay will be available in 10 working days.
For the Com.Pl.i.t DX Lung Assay we need a paraffin block that contains the tumor tissue. We need one paraffin block or four unstained paraffin sections of 3μm: in positive charged slides (air dried, not baked), placed on top of the slide, without folds and six unstained slides of 10μm.
The sample should be kept at room temperature (25°C). During the summer period we recommend to have an ice pack in the Kit (The ice pack should not directly touch the sample).
For information about the cost coverage of the test you should contact your personal insurance.
The payment can be made by bank transfer or credit/debit card.
Genekor is responsible for all the necessary procedures of the pick-up and return of the patient’s specimen. To arrange your sample pick-up and return, contact us or complete the appropriate Test Order Form.
Your results will be shared with the ordering physician via e-mail.
Genekor Medical S.A. is certified with ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012, which require the written consent of each patient for the use of his/her genetic material for testing.
On the Genomic Alterations Section a more detailed interpretation about the Genomic Alterations identified is contained, including frequencing ratios, biological impact and related targeted therapies.
On the Clinical Trials Section all the currently available clinical trials are reported according to the molecular profile of the patient’s tumor.
Furthermore, details about the methodology of the assay are reported on the Methodology Section.
Ask your physician if you are eligible for the Com.Pl.i.t DX Lung test.
Tissue from surgery or biopsy which is embedded in paraffin (FFPET) is required for this test. Your sample will be collected per your physicans' instructions.
Your sample will arrive to our accredited laboratory and your report will be generated and sent to you and your physician in 10 working days.
Your report will be electronically released to your physician via email and/or uploaded to our secure portal, and to you via email or mail.
Com.Pl.i.t DX Lung is designed in order to achieve maximum sensitivity and specificity. All findings are classified using the most reliable and updated databases and in silico analysis algorithms.
Advanced Next Generation Sequencing technology, also known as NGS, is used to fully analyze a panel of genes that are related to targeted treatments. Analysis of gene fusions is also included in Com.Pl.i.t DX, providing comprehensive and reliable information to patients and physicians.
For more scientific and technical information you can contact us: scientific.support@genekor.com
